WATCH: Vance speaks at a manufacturing facility in key election state Iowa


DES MOINES, Iowa (AP) — Vice President JD Vance, making his first trip to Iowa since taking office, promoted the administration’s tax and tariff policies while framing the GOP as being on the side of working-class voters as he campaigned in the state where Republicans in less than two years will cast the initial votes to pick their party’s next presidential nominee.

Watch Vance’s remarks in the video player above.

Standing before hundreds of supporters at a steel manufacturing facility, Vance repeatedly drew a contrast between Iowa Republican Rep. Zach Nunn and his Democratic challenger, telling the crowd that Nunn and the Trump administration were “fighting for you instead of fighting against you” as he attacked Democrats on issues of immigration and fraud.

READ MORE: What to watch in Tuesday’s elections in Indiana, Ohio and Michigan

“This is not a normal election. This is not a normal political environment,” said Vance, who is seen as one of the GOP’s strongest potential candidates for president in 2028. “This is a contest between a party that wants to take all of your money and give it to illegal aliens and a contest between gentlemen like Zach Nunn who fight every single day for you.”+

Nunn faces a competitive race to keep his Des Moines-area seat in the November midterms. Vance frequently heaped praise on Nunn, calling him “one of those guys who does the right thing, not just when the cameras are on, but when the cameras are off, too.”

The visit to Iowa offered Vance an opportunity to test his reception before Iowa’s voters, whose leadoff caucuses give them an outsize role in determining the next presidential nominee. Campaigning for a local congressman in his role as vice president provided him with a chance to make an impression on Iowa Republicans, seasoned evaluators of those who seek the nation’s highest office, before the campaign begins in earnest.

Vance’s appearance comes days after Texas Sen. Ted Cruz, who is also considered a possible 2028 candidate, spoke to a group of evangelical Christians who are influential in Iowa’s GOP contest.

READ MORE: Trump’s influence tested in Indiana primaries after failed redistricting push

Jimmy Centers, a Des Moines-based Republican political consultant, said that the 2028 contest is “light-years away” but that the Republicans who hear Vance speak on Tuesday will be evaluating how he might measure up in an election for the White House.

“I certainly think, as of right now, Vice President Vance would probably be a straw-poll winner of Iowa Republicans for 2028. But I don’t think anyone is saying, ‘We won’t consider anybody else,'” Centers said.

Vance’s visit comes as higher prices for gas and fertilizer hit Iowans

Vance, who has not said whether he will run for president in 2028, appeared with Nunn at Ex-Guard Industries in Des Moines.

The vice president’s visit follows a trip Trump made in January to tout the administration’s tax cuts, part of a string of stops they’re making this year on economic issues before midterm elections that will determine control of Congress.

READ MORE: Trump’s influence tested in Indiana primaries after failed redistricting push

But Vance’s visit comes when his own political prospects — and the message he delivered on the economy — have been complicated by the war in Iran.

The vice president, who has long been skeptical of foreign military interventions, has seemed a reluctant defender of the 9-week-old war, for which Trump has struggled to find an off-ramp. Iowans, like much of the rest of the country, are grappling with higher gas prices because of the conflict. But the state’s farmers are also feeling the pinch of high fertilizer costs from the war and have been hurt by tariffs Trump has imposed.

Vance made a nod to those cost struggles in his remarks, saying that he’s aware of the rising price of fertilizer and noted: “We got a little blip.” Nonetheless, he said the administration is “working on it.”

While Iowa’s farmers have steadfastly supported the president, they have been looking to the White House for assurances that the current troubles won’t last.

Vance, who met with Iowa Gold Star families just before his public remarks, also became emotional as he discussed the sacrifices made by fallen U.S. soldiers and their families. He talked about wondering how he would react if his 6-year-old son, Vivek, who accompanied him Tuesday, told him later in life that he wanted to enlist, saying he would be “so proud of him” but also “so terrified.”

“Every time that a person gives the ultimate sacrifice to the United States of America … there’s a whole crew of people who love them the same way that we all love every single member of our family,” he said, adding that “part of how we earn that incredible sacrifice” is “by making this country’s politics and government worthy of the people who put on the uniform and will never see their loved ones again.”

Earlier Tuesday, Vance, who represented Ohio in the U.S. Senate before becoming vice president, stopped first in Cincinnati to vote in Ohio’s primary elections and told reporters he was voting for Vivek Ramaswamy in the governor’s race. Asked about U.S. Sen. Jon Husted, who’s running in a special election to serve out the remainder of Vance’s term, Vance said he thinks Husted’s “going to do a great job” and has been “good for Ohio.”

His 6-year-old son, meanwhile, filled out a ballot for children, which the vice president showed to the poll workers when he cast his own ballot. “He voted for the Easter bunny over the tooth fairy,” he said of his son.

Before arriving in Iowa, Vance also appeared in Oklahoma City to hold a fundraiser in his role as finance chair of the Republican National Committee.

It’s ‘awfully, awfully early’ in the road to 2028

Kim Schmett, a longtime Iowa GOP activist, said the presidential cycle starts “deceptively slow.”

He said Trump’s Make America Great Again political movement “is very alive and going here” in Iowa, which would benefit Vance — as well as Secretary of State Marco Rubio, who is also thought to be a potential candidate.

“I think there’s going to be a lot of MAGA support,” he said. “And Vice President Vance and Marco Rubio seem to be the recipients of where that is going at the moment.”

But Schmett cautioned, “It’s awfully, awfully early in the process.”

On the Democratic side, at least half a dozen presidential prospects have been making visits to the states with the earliest presidential primary contests, including recent visits to Iowa by former Transportation Secretary Pete Buttigieg and Michigan U.S. Sen. Elissa Slotkin.

Meanwhile, potential Republican presidential candidates “are treading very lightly,” said GOP strategist Alex Conant, who worked on Rubio’s 2016 presidential campaign.

“I think Republicans are going to be very reluctant to get in Trump’s way until Trump gives the green light for the campaign to start,” Conant said.

That means much of the groundwork to meet with donors or activists or recruit political staffers might happen slowly and subtly – for now.

After the midterms? Conant said: “It’ll be irresistible.”

Associated Press writer Seung Min Kim contributed to this report from Washington.

A free press is a cornerstone of a healthy democracy.

Support trusted journalism and civil dialogue.


Donate now

Free Training

Source link

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility


Real-time Estimate


Cboe Europe



07:06:01 2026-04-30 am EDT

5-day change

1st Jan Change

115.28 CHF

+1.71%

Intraday chart for Novartis AG

-1.12%

+4.91%

Published on 04/30/2026
at 07:00 am EDT

Dow Jones

(MORE TO FOLLOW) Dow Jones Newswires

April 30, 2026 07:00 ET (11:00 GMT)

Dow Jones logo
© Dow Jones –
2026

DurationAuto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax.

PeriodDayWeek

Chart Novartis AGLogo Novartis AG
Novartis AG is one of the world’s leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows:

– oncology (30.9%);

– immunology (18.9%);

– cardiovascular, renal and metabolic diseases (16.4%);

– neuroscience (11%).

The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products.

At the end of 2025, Novartis AG had over 31 production sites worldwide.

Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

SellConsensusBuy

Last Close Price

143.45USD

Average target price

153.80USD

Spread / Average Target

+7.21%

Quarterly revenue – Rate of surprise

Indices
Europe

America

Asia

Download from Apple Store

OUR EXPERTS ARE HERE FOR YOU

Monday – Friday 9am-12pm / 2pm-6pm GMT + 1

MarketScreener, Stock Market Live
Legal information
|
Cookie settings
|
MarketScreener Blog
|
About us
|
Copyright © 2026 Surperformance SAS. All rights reserved.

Stock quotes are provided by Factset, Morningstar and S&P Capital IQ

Select your edition

All financial news and data tailored to specific country editions

Free Training

Source link

WesPro JCB Celebrates Grand Opening of Its Second Atlanta Area Facility : CEG


Cutting the ribbon on the new store (L-R) are Gareth Lumsdaine, vice president of distribution development, JCB North America; Graeme Macdonald, CEO, JCB; Wesley Scott, owner, WesPro JCB; and Richard Fox-Marrs, president and CEO, JCB North America.

JCB photo

Cutting the ribbon on the new store (L-R) are Gareth Lumsdaine, vice president of distribution development, JCB North America; Graeme Macdonald, CEO, JCB; Wesley Scott, owner, WesPro JCB; and Richard Fox-Marrs, president and CEO, JCB North America.

WesPro JCB celebrated the grand opening of its new Norcross, Ga., facility, its second in the Atlanta area, marking a significant milestone in its continued growth and expansion across the Southeast.

The event welcomed customers, local officials and industry partners to officially open the 14,000-sq.-ft. site, designed to enhance sales experience, parts availability, service capabilities and overall support for construction and agricultural customers across metro Atlanta.

The $14 million facility, located at 5493 Goshen Springs Rd., represents the latest investment in JCB‘s expanding American network, strengthening support for customers and dealers in key United States markets.

“Our investment in facilities like WesPro JCB and our $1 billion Texas facility reflects our commitment to manufacturing in the United States and supporting American industry,” said Graeme Macdonald, CEO of JCB. “We are investing at scale to build a stronger American business that delivers equipment, supports our dealers and serves customers across construction and agriculture.”

Expanding Capabilities to Support Customers

The Norcross facility, situated on a 3-acre site along Interstate 85, is designed to improve uptime and service responsiveness for customers across the region. Strategically located along one of metro Atlanta’s busiest transportation corridors, it enhances accessibility and enables quicker response to customer needs.

The site includes a 2,000-sq.-ft. parts warehouse, 10 service bays and the capability to repair the largest JCB excavators and machinery, supporting faster diagnostics, more efficient repairs and reduced downtime.

“Our commitment to manufacturing in America for American customers goes hand in hand with investing in the facilities and dealer network that support our equipment throughout its lifecycle,” said Richard Fox-Marrs, president and CEO of JCB North America. “Facilities like WesPro’s Norcross location ensure we are delivering the service, parts availability and expertise our customers rely on long after the initial purchase.”

Expanding Presence in Key Markets

The Norcross facility is part of JCB’s expanding presence across the United States, alongside continued investment in manufacturing and dealer development in key markets. In addition to its new factory in San Antonio, Texas, JCB has established a growing dealer and warehousing presence in north Texas, southern California and Chicago, with plans for future expansion in major metropolitan areas.

“JCB has deep roots in Georgia, and WesPro is proud to be the newest branch of that continued growth,” said Wesley Scott, owner of WesPro JCB. “This investment strengthens our ability to support our customers with the sales, service and expertise they depend on every day.”

For more information, visit wesprojcb.com.

Free Training

Source link

Taiwanese Battery Manufacturer Selects Liberal for New U.S. Facility


TOPEKA – The Kansas Department of Commerce today announced Apogee Power, a Taiwan-based energy technology and advanced battery manufacturer, has selected Liberal as the location for its new U.S. manufacturing and assembly facility. The company will invest almost $16 million over the next three to five years and create 80 new jobs.

“In Kansas, we have a strong advanced battery ecosystem, talented workforce and central location that companies from around the world are eagerly looking to access,” Lieutenant Governor and Secretary of Commerce David Toland said. “Apogee’s decision to expand their work into Liberal highlights the strength of our rural communities and Kansas’ ability to compete on a global scale.”

The facility, located in Liberal’s industrial corridor, will support the assembly, testing and distribution of Apogee’s lithium iron phosphate (LFP) battery systems and related energy storage technologies for commercial, industrial and grid-scale applications across the United States. The company anticipates hiring 30 employees in the initial phase — with additional positions coming online as production ramps up.

Apogee is currently preparing the Liberal facility for production and expects to begin operations this summer. The facility represents Apogee’s first U.S. manufacturing presence and reflects their long-term commitment to serving customers from a centralized and cost-competitive location.

Apogee Power CEO Wen Lin, Apogee Energy CEO George Shen and other stakeholders were in Topeka recently to discuss the company’s investment and their desire to recruit additional suppliers from Taiwan to the Liberal area and other possible locations in Kansas. This followed a trade mission to Taiwan in September 2025, when Lieutenant Governor and Secretary of Commerce David Toland and other state and local officials visited Apogee Power’s headquarters in Taipei to meet their team and finalize the project details.

“Establishing a U.S. manufacturing footprint is a critical step in Apogee’s global growth strategy,” Apogee Power CEO Wen Lin said. “Liberal offers the infrastructure, workforce and community partnership we were looking for — along with a strong understanding of energy-intensive manufacturing. This location allows us to serve U.S. customers more efficiently while building a durable, long-term presence in the American market.”

Local leaders emphasized the collaborative approach that helped secure the project.

“We’re excited to welcome Apogee to Liberal,” Seward County Development Corporation Executive Director Eli Svaty said. “This investment builds on our region’s strengths in energy, logistics and advanced manufacturing. It also signals that global technology companies see value in smaller, execution-focused communities that can move quickly and deliver.”

Free Training

Source link

Samsung Biologics completes acquisition of US manufacturing facility



Officials cut a ceremonial ribbon during an event marking Samsung Biologics’ acquisition of a biopharmaceutical manufacturing plant in Rockville, Md., Tuesday (local time). From front row fifth from left, are Korean Ambassador to the United States Kang Kyung-wha, Samsung Biologics CEO John Rim, Maryland Gov. Wes Moore and Congresswoman April Delaney. Courtesy of Samsung Biologics

Officials cut a ceremonial ribbon during an event marking Samsung Biologics’ acquisition of a biopharmaceutical manufacturing plant in Rockville, Md., Tuesday (local time). From front row fifth from left, are Korean Ambassador to the United States Kang Kyung-wha, Samsung Biologics CEO John Rim, Maryland Gov. Wes Moore and Congresswoman April Delaney. Courtesy of Samsung Biologics

Samsung Biologics has closed the deal to acquire GSK’s facility in Rockville, Md., establishing the biopharmaceutical firm’s first manufacturing base in the United States, the company said Wednesday.

In its regulatory filing, the Korean company said its wholly owned subsidiary Samsung Biologics America has completed the acquisition of Human Genome Sciences, which owns a drug substance manufacturing facility in the U.S. from GSK for a total of $353.1 million.

Of the amount, $280 million is for the acquisition of the facility and equity, while the remaining $73.1 million was paid for the transfer of inventories and raw materials held by Human Genome Sciences.

The deal’s closure came three months after Samsung Biologics announced the acquisition on Dec. 22 last year, as part of its efforts to mitigate risks stemming from the Trump administration’s tariffs on biopharmaceuticals, as well as to expand its contract drug manufacturing capacity beyond Korea.

Samsung Biologics' biopharmaceutical manufacturing site in Rockville, Md. / Courtesy of Samsung Biologics

Samsung Biologics’ biopharmaceutical manufacturing site in Rockville, Md. / Courtesy of Samsung Biologics

The Rockville site is comprised of two manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales.

The acquisition increased Samsung Biologics’ total global manufacturing capacity to 845,000 liters per year from 785,000 liters.

Despite being one of the world’s largest contract drug manufacturers, Samsung Biologics had been exposed to supply chain risks, as all of its manufacturing facilities were located in Korea prior to the acquisition.

With the acquisition, Samsung Biologics will be able to provide clients with more flexible multi-site manufacturing options in both the U.S. and Korea, strengthening collaboration with North American customers and enhancing its ability to respond to regional changes in the supply environment.

Samsung Biologics said it will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, as well as serving additional contract manufacturing needs. The company plans further investments to expand the site’s capacity and upgrade technologies. It will retain more than 500 employees at the site to ensure operational continuity and stability.

Samsung Biologics CEO John Rim speaks during a ceremony marking the company's acquisition of a biopharmaceutical manufacturing plant in Rockville, Md., Tuesday (local time). Courtesy of Samsung Biologics

Samsung Biologics CEO John Rim speaks during a ceremony marking the company’s acquisition of a biopharmaceutical manufacturing plant in Rockville, Md., Tuesday (local time). Courtesy of Samsung Biologics

“This represents a meaningful step in expanding our U.S. manufacturing footprint,” Samsung Biologics CEO John Rim said.

“The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network. … The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network.”

Free Training

Source link

UCB to Invest $2 Billion in Georgia, Establish First U.S. Manufacturing Facility


Georgia seal

ATLANTA – March 24, 2026 – Governor Brian P. Kemp today announced that global biopharmaceutical giant UCB, Inc. is planning a significant investment of $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs over the next several years at the Rowen Foundation’s state-of-the-art, 2,000-acre science and learning campus in Gwinnett County.

“When we met with UCB leadership earlier this year in Belgium, we discussed how the Peach State would be the right partner for their visionary plans in the U.S. that will benefit both patients and hardworking Georgians,” said Governor Brian Kemp. “UCB’s announcement is also a significant milestone for our life sciences industry, representing one of the largest investments in state history and establishing both the Rowen facility and Georgia as a true hub of innovation in this field.”

A global biopharmaceutical company based in Belgium, UCB’s North American headquarters are located in Smyrna and currently support more than 400 jobs. UCB’s expertise spans neurology and immunology.

“This decision reflects our confidence in UCB’s long-term growth and our deep-rooted commitment to the United States,” said Jean-Christophe Tellier, CEO of UCB. “By investing in Georgia, where our U.S. headquarters have been based for more than three decades, we are strengthening our biologics manufacturing capabilities, supporting our innovation pipeline, and creating high-quality jobs in a state that offers outstanding talent, a strong manufacturing tradition, and an ecosystem designed for sustainable, long-term success. This project is expected to generate approximately $5 billion in total economic impact, reflecting the broader value it will create for the region and its communities.”

UCB’s new manufacturing footprint will be located at Rowen, serving as an anchor tenant for this 2,000-acre planned community in metro Atlanta designed to foster collaboration, knowledge sharing, and innovation. The cutting-edge campus will use a digital-first approach by leveraging AI, robotics, and automation while also prioritizing efficiency in the use of any natural resources.  

“We are thrilled that UCB has chosen Gwinnett County to advance its global operations and pioneering innovations,” said Chairwoman Nicole Love Hendrickson, Gwinnett County Board of Commissioners. “An investment of this magnitude was exactly what we envisioned when we committed to establishing Rowen as a hub for collaboration and discovery. As one of the most dynamic and diverse counties in the nation, Gwinnett connects UCB to a highly skilled, globally connected talent pool. UCB’s decision to invest here makes clear what industry leaders increasingly recognize: Gwinnett County is a partner in progress, committed to world-class infrastructure, premier services, and quality of life that support continued growth and success.”

“UCB’s decision to locate their new manufacturing operation in Gwinnett County is a testament to the strength of our entire region to support the growth of the life sciences industry,” said Katie Kirkpatrick, President and CEO of the Metro Atlanta Chamber. “UCB’s innovation, talent, and strategic investment show that metro Atlanta is not just a hub for life sciences today, but a place where the breakthroughs of tomorrow are taking shape.”

Project Director EJane Caraway represented the Georgia Department of Economic Development’s (GDEcD) Global Commerce team on this competitive project in partnership with Partnership Gwinnett, Metro Atlanta Chamber, Georgia Quick Start, and Georgia Power.

“For more than a century, UCB has been a leader in biopharmaceutical innovation,” said GDEcD Commissioner Pat Wilson. “Georgia’s growing life sciences ecosystem and collaborative approach to economic development connect companies with world-class partners in research, education, logistics, and infrastructure. Together with our focus on being the Top State for Talent, it’s why innovators like UCB choose Georgia to advance discoveries from R&D to real-world impact.”

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Free Training

Source link

GE Aerospace to invest $18M at Batesville facility


GE Aerospace to invest $18M at Batesville facility

Published 11:42 am Friday, March 13, 2026

GE Aerospace announced plans to invest $1 billion in its U.S. manufacturing sites and suppliers in 2026, including $18 million at its facility in Batesville.

The investment will fund new and upgraded production equipment and tooling to expand ceramic matrix composite component manufacturing, along with additional inspection equipment and facility improvements. Ceramic matrix composite engine parts are about one-third the weight of traditional metal components and can withstand temperatures up to 500 degrees higher.

“What we make in Batesville goes a long way in helping power the newest narrowbody and widebody engines around the world, and this investment allows us to deliver for our customers, U.S. manufacturing, and the region,” said Matt Shambaugh, site leader for GE Aerospace in Batesville.

The Batesville site plays a key role in ramping up production of the CFM LEAP engine used on narrowbody aircraft and also produces components for widebody aircraft. Over the past three years, GE Aerospace has announced plans to invest more than $40 million in the Batesville facility.

The company also plans to hire 5,000 workers across the United States this year. More than 30 positions are currently open at the Batesville site.

Free Training

Source link

SICCET USA Chooses Grove City for First U.S. Manufacturing Facility


GROVE CITY, Ohio — SICCET USA has announced plans to open its first U.S. manufacturing facility in Grove City, marking a significant investment by the Italy-based company into the American market.

The new 20,000-square-foot operation represents a $2 million investment and is expected to create 15 new jobs in Franklin County. The facility will manufacture high-performance cables used to monitor and control temperature in demanding environments, including aircraft engines, power plants and industrial food equipment.

SICCET USA is the American subsidiary of SICCET SRL, a longtime European supplier of temperature sensor cable solutions. The company specializes in thermocouple and RTD cable manufacturing — critical components in ensuring performance, precision and safety in modern industrial systems.

Company leadership said the decision to locate in Grove City was driven by the Columbus Region’s central location, robust logistics network and access to a skilled workforce.

Quick Action by Circleville Firefighters Prevents House Fire from SpreadingTrendingQuick Action by Circleville Firefighters Prevents House Fire from Spreading

“SICCET USA is proud to begin our U.S. manufacturing journey in Grove City,” said Ivan Dall’Armellina, president of SICCET USA and co-owner of SICCET SRL. “This location offers strong infrastructure, a collaborative business environment and proximity to key markets that are vital for our long-term growth.”

Grove City Mayor Richard “Ike” Stage welcomed the announcement, noting that the community continues to attract advanced manufacturing firms seeking long-term growth opportunities.

Regional economic development leaders say the investment reflects a broader trend of international companies choosing central Ohio as a gateway into the North American market.

Deborah Scherer, senior vice president of global trade and investment at the Columbus Partnership, said SICCET’s move underscores growing global confidence in the region’s industrial base and logistics strengths.

JobsOhio President and CEO J.P. Nauseef added that Ohio’s workforce, infrastructure and global reach continue to attract world-class manufacturers looking to expand operations in the United States. JobsOhio partnered in supporting the project.

The Grove City facility positions SICCET to better serve its expanding North American customer base as demand grows for specialized, high-performance industrial components amid a resurgence in U.S. manufacturing.

Free Training

Source link

Japanese manufacturer selects San Antonio for first U.S. facility, headquarters


Sanko Texas Corporation will break ground on its first U.S. plant in San Antonio, highlighting the city’s economic growth and strengthening U.S.-Japan trade ties.

SAN ANTONIO — Sanko Texas Corporation, a Japanese manufacturer, will break ground Wednesday on its first U.S. manufacturing facility, marking the company’s initial expansion into the United States and the establishment of its U.S. headquarters in San Antonio.

The groundbreaking ceremony is scheduled for 11:15 a.m. Wednesday, Feb. 11, 2026, at the Sanko Texas Corporation site at 16586 Watson Road in southern Bexar County.

Local and regional officials said the investment reflects San Antonio’s strengths in workforce talent, infrastructure and business climate, which have helped attract global manufacturers. By choosing San Antonio, Sanko joins a rapidly growing advanced manufacturing sector in Texas that plays a significant role in regional economic growth.

The project also highlights economic ties between the region and Japan, while reflecting coordinated efforts by local and regional partners to attract international investment.

Expected to attend the ceremony are Bexar County Judge Peter Sakai; San Antonio Mayor Gina Ortiz Jones; Bexar County Commissioner Rebecca Clay-Flores of Precinct 1; San Antonio City Councilwoman Phyllis Viagran of District 3; members of Sanko leadership and local business leaders.

Free Training

Source link

PharmaEssentia Plans New U.S. Manufacturing Facility In Puerto Rico



PharmaEssentia Puerto RicoPharmaEssentia Puerto Rico(Photo: PharmaEssentia)

Taiwan-based PharmaEssentia Corporation and its Massachusetts-based U.S. subsidiary PharmaEssentia USA Corporation will invest approximately $46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico. PharmaEssentia is a global biopharmaceutical company that develops novel biologics for hematology and oncology.

PharmaEssentiaPharmaEssentiaKo-Chung Lin, Ph.D.
Founder, CEO / US General Manager, PharmaEssentia

The Puerto Rico operation will support the company’s global manufacturing expansion strategy and is intended to serve as a future manufacturing center for the U.S. market and long-term global demand for BESREMi®, a treatment for adults with polycythemia vera (PV). The project reflects sustained global demand growth for the biologic, particularly in the U.S., as well as the potential additional demand growth from regulatory approvals for new uses.

Puerto Rico is widely recognized as a leading global hub for pharmaceutical manufacturing, hosting a strong ecosystem of experienced talent, infrastructure, and regulatory expertise. The planned manufacturing facility is expected to provide several long-term strategic benefits for PharmaEssentia, including enhanced supply security, increased operational flexibility, improved cost efficiency, and scalable manufacturing capacity to support future growth.

“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia as we continue to strengthen supply resilience, scalability, and geographic diversification,” said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer of PharmaEssentia. “We are proud to take this important step toward establishing U.S.-based manufacturing, with Puerto Rico serving as a future center for the U.S. market. This investment underscores our long-term commitment to reliably serving patients worldwide as demand for BESREMi® continues to grow.”

“PharmaEssentia’s decision to establish a manufacturing operation in Puerto Rico underscores the island’s role as a strategic U.S. hub for life sciences and advanced manufacturing,” said Governor of Puerto Rico Jennifer González. “This investment strengthens supply-chain resilience, creates high-value jobs, and reinforces Puerto Rico’s position as a trusted location for biopharmaceutical innovation and production serving patients in the United States and around the world.”

Read more about corporate expansion in the pharmaceuticals industry on Business Facilities.

Free Training

Source link